PERTH, Australia – Australia's biopharma and medical device industries breathed a collective sigh of relief that the Australian Government's 2017 budget announced May 9 left the much-loved R&D tax incentive untouched. Read More
LONDON – In a Franco-Sino tie-up Pharnext SA and Tasly Pharmaceutical Co. Ltd. signed a three-part agreement, which will see the Chinese pharma invest up to $44 million in a combination of equity, a joint venture, and the clinical development of Pharnext's lead program, PXT-3003, in China. Read More
A new way of conceptualizing lymphedema has led to the discovery of a new way to treat it. The approach is now being tested in a phase II trial. Read More
While last year's positive readout from the first part of Array Biopharma Inc.'s phase III COLUMBUS trial testing binimetinib and encorafenib in BRAF-mutant advanced, unresectable or metastatic melanoma cleared the way for regulatory filings, supplementary results from the study's second part, released late Tuesday, could bolster the combination's prospects for approval and market penetration. Read More
The U.S. Senate Health, Education, Labor and Pensions (HELP) Committee will hold a hearing on drug spending in the near future, HELP Chairman Lamar Alexander (R-Tenn.) informed members Tuesday. The committee will look at what is currently being spent on drugs, what types of drugs are raising the tab and what projections are for future spending. Read More
Urogen Pharma Ltd., of Ra'anana, Israel, said it closed its IPO of about 5.1 million shares priced at $13 apiece, including the exercise in full of the underwriters' option to purchase an additional 671,005 shares, resulting in gross proceeds of about $66.9 million. Read More
Cempra Inc., of Chapel Hill, N.C., presented at the Association for Research in Vision and Ophthalmology meeting in Baltimore data highlighting topical ophthalmic formulations of solithromycin in preclinical models of activity, tolerability and pharmacokinetics in the eye. Read More
Sierra Oncology Inc., of Vancouver, British Columbia, said it was cleared by U.K. regulators to amend the two ongoing phase I trials for Chk1 inhibitor SRA-737 to include cohort expansions of prospectively selected patients with tumors identified to have genetic aberrations hypothesized to confer sensitivity to Chk1 inhibition. Read More
Jazz Pharmaceuticals plc, of Dublin, reported that total revenues for the first quarter increased 12 percent to $376 million in line with the Street expectations. Read More
